- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01345266
Characterisation of Healthy Volunteers, Asthma and Chronic Obstructive Pulmonary Disease Patients for Inhalation Profile, Pharyngometry, Spirometric Indices and Lung Morphometry
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Antwerpen, Belgium, 2060
- GSK Investigational Site
-
Edegem, Belgium, 2650
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
A subject will be eligible for inclusion in this study only if all of the following criteria apply.
- All volunteers must be aged between 21 to 70 years inclusive and be competent to understand and give informed consent.
- All female volunteers of child bearing potential must have provided a negative pregnancy test before inclusion and prior to any HRCT scan.
- Body weight < 120 kg and BMI within the range 18 - 35 kg/m2 (inclusive).
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
- Available to complete the study
- Subject will then be included only if they fulfil all criteria for the following relevant cohort Healthy: Cohort
- Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history and physical. A subject with a clinical abnormality or parameters outside the reference range for the population being studied may be included if the Investigator agrees that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
- Non-smokers (never smoked or not smoking for >12 months with <1 pack year history) (Pack years = (cigarettes per day smoked/20) x number of years smoked))
- No history of a chronic respiratory disorder.
- No history of acute respiratory disease within four weeks prior to inclusion.
- No history of breathing problems such as a history of asthma, unless the asthma was in childhood and has now completely resolved, no longer requiring maintenance or intermittent therapy.
- No other significant medical disorder that may affect the respiratory system or that causes significant disability.
Asthmatic: Cohort
- Clinically diagnosed with asthma, for at least 6 months, stratified as either: mild, moderate or severe, based on current treatment, using the British Thoracic Society - - Guidelines on Asthma [BTS, 2009]. For inhaled steroid equivalence to budesonide please refer to the GINA guidelines [GINA, 2008]
- Mild, defined Step 1 or 2 by BTS Asthma Guidelines
- Moderate, defined as step 3 by BTS Asthma Guidelines
- Severe, defined as step 4 or 5 by BTS Asthma Guidelines
- Non-smokers (never smoked or not smoking for >12 months with <1 pack year history (Pack years = (cigarettes per day smoked/20) x number of years smoked))
- Able to withhold from short acting bronchodilators for 6 hours and long acting bronchodilators for 12 hours before study assessments
- No history of acute respiratory disease within four weeks prior to inclusion.
- No history of any other inflammatory lung condition or carcinoma of the lung.
- No exacerbation of disease requiring hospitalisation within previous four weeks.
COPD: Cohort
- Clinically diagnosed COPD, for at least 6 months prior to screening, either: mild, moderate or severe/very severe (stage I, II, III/IV) COPD as defined by GOLD guidelines [GOLD 2008]. The following lung function criteria are post bronchodilator
Stage I:
- Mild COPD. FEV1/FVC < 70%, FEV1 ≥ 80% predicted with or without chronic symptoms (cough, sputum production) Stage II
- Moderate COPD. FEV1/FVC < 70%. 50% ≤ FEV1 < 80% predicted with or without chronic symptoms (cough, sputum production) Stage III and IV
- Severe COPD. FEV1/FVC < 70%. 30% ≤ FEV1 < 50% predicted with or without chronic symptoms (cough, sputum production)
- Very Severe COPD.FEV1/FVC < 70%, FEV1 < 30% predicted or FEV1 < 50% predicted plus chronic respiratory failure
- Subject is a smoker or an ex-smoker with a smoking history of at least 10 pack years (Pack years = (cigarettes per day smoked/20) x number of years smoked)).
- No history of acute respiratory disease within four weeks prior to inclusion
- No history of any other inflammatory lung condition or carcinoma of the lung.
- No exacerbation of disease requiring hospitalisation within previous four weeks.
- Able to withhold from short acting bronchodilators for 6 hours and long acting bronchodilators for 12 hours before study assessments
Exclusion Criteria:
A subject will not be eligible for inclusion in this study if any of the following criteria apply:
- As a result of the medical interview, physical examination or screening investigations, the physician responsible considers the volunteer unfit for the study.
- Any pregnant female
- Volunteers who have a past or present disease, which as judged by the Investigator, may affect subject safety or influence the outcome of the study.
- The subject has received an investigational drug or participated in any other research trial within 30 days or five half-lives, or twice the duration of the biological effect of any drug (whichever is longer).
- The subject that has both asthma and COPD.
- Previous inclusion in a research and/or medical protocol involving nuclear medicine,
- Any Radiological investigations with significant radiation burden (a significant radiation burden being defined as ICRP category IIb or above: No more than 10 mSv in addition to natural background radiation, in the previous 3 years including the dose from this study).
- The subject has a history of alcohol or drug abuse.
- The subject has had a respiratory tract infection within four weeks of the start of the study.
- The subject has a history of claustrophobia.
- The subject is unable to perform the Multi Channel Recorder and/or Pharyngometry assessments correctly.
- The subject has a known allergy or hypersensitivity to milk protein.
- Unwillingness or inability to follow any of the procedures outlined in the protocol.
- Subject is kept under regulatory of judicial order in an institution.
- Subject is mentally or legally incapacitated.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Inhalation Profiling
All subjects have Inhaltion profiling, there are no other arms.
|
All subects recieve Inhaltion Profiling there are no interventions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Inhaltion Profile Recording (IPR): Measures will be Peak Pressure Drop (kPa), Peak Inspiratory Flow Rate (L/min), Inhaled Volume (L), Inhalation time (s) Average Inhalation flow rate (L/min)
Time Frame: 24 hours
|
To characterise the inhalation profiles of healthy volunteers, volunteers with mild, moderate and severe asthma and volunteers with mild, moderate and severe COPD, through the novel DPI, using the IPR
|
24 hours
|
Pharangometry: Measures will be, Distance (cm) Volume (cm3) Average cross sectional area (cm2)
Time Frame: 24 hours
|
To characterise the inhalation profiles of healthy volunteers, volunteers with mild, moderate and severe asthma and volunteers with mild, moderate and severe COPD, using pharangometry
|
24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HRCT scans: Measures are Total Lung Capacity (TLC) and Functional Residual capacity (FRC)
Time Frame: 24 hours
|
Exploratory: To provide data from HRCT scans, spirometry and plethysmography measures which will enable further work in the mapping of the small and large airways and deliver 3D geometries of these airways.
|
24 hours
|
Lung function indices by spirometry: Measures, FEV1, Vmax25 and 50, PEFR, PIFR
Time Frame: 24 hours
|
Exploratory: To provide data from HRCT scans, spirometry and plethysmography measures which will enable further work in the mapping of the small and large airways and deliver 3D geometries of these airways.
|
24 hours
|
Whole body plethysmography: Measures include.Volume: total lung, residual volume, functional reserve volume, Impedance - generation 0 to 6, Resistance - generation 0 to 6 and Diffusion.
Time Frame: 24 hours
|
Exploratory: To provide data from HRCT scans, spirometry and plethysmography measures which will enable further work in the mapping of the small and large airways and deliver 3D geometries of these airways.
|
24 hours
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Prime D, de Backer W, Hamilton M, Cahn A, Preece A, Kelleher D, Baines A, Moore A, Brealey N, Moynihan J. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA(R) Dry Powder Inhaler. J Aerosol Med Pulm Drug Deliv. 2015 Dec;28(6):486-97. doi: 10.1089/jamp.2015.1224. Epub 2015 Sep 15.
- Hamilton M, Leggett R, Pang C, Charles S, Gillett B, Prime D. In Vitro Dosing Performance of the ELLIPTA(R) Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung). J Aerosol Med Pulm Drug Deliv. 2015 Dec;28(6):498-506. doi: 10.1089/jamp.2015.1225. Epub 2015 Sep 15.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 113817
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Disease, Chronic Obstructive
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on Inhalation Profiling
-
Karolinska InstitutetActive, not recruitingChronic Atrophic GastritisSweden
-
University Health Network, TorontoActive, not recruitingCarcinoma, Pancreatic DuctalCanada
-
Avera McKennan Hospital & University Health CenterWithdrawnMetastatic Breast Cancer | Breast Tumor | Advanced Gynecologic CancerUnited States
-
National Cancer Institute (NCI)CompletedProstate CancerUnited States
-
Columbia UniversityRecruitingChildhood Obesity | Morbid ObesityUnited States
-
Dana-Farber Cancer InstituteActive, not recruitingRecurrent, Refractory, or High Risk Leukemias | Matched Targeted TherapyUnited States
-
Samsung Medical CenterCompleted
-
National Institutes of Health Clinical Center (CC)National Cancer Institute (NCI)Completed
-
University of HelsinkiHelsinki University Central HospitalRecruiting
-
Odense University HospitalRecruiting